
David J Curchin1, Victoria R Harris2, Christopher J McCormack3, Saxon D Smith1,2

Abstract

Objectives: To estimate the incidence of cutaneous malignant melanoma in Victoria; to examine trends in its incidence over the past 30 years. Secondary objectives were to examine the anatomic location and thickness of invasive melanoma tumours during the same period.

Design: Population-based, descriptive analysis of Victorian Cancer Registry data.


Main outcome measures: Age-standardised incidence of invasive melanoma; estimated annual percentage changes in incidence.

Results: In 2015, the incidence of invasive melanoma in Victoria was 52.9 cases per 100 000 men and 39.2 cases per 100 000 women. Since the mid-1990s, the incidence for men increased annually by 0.9% (95% CI, 0.3–1.5%), but for women there was no significant change (estimated annual percentage change, −0.1%; 95% CI, −0.8% to 0.5%). The incidence of invasive melanoma has been declining in age groups under 55 years of age since 1996 (overall annual change, −1.7%; 95% CI, −2.5% to −0.9%), but is still increasing in those over 55 (overall annual change, 1.6%; 95% CI, 1.0–2.2%). The most frequent site of tumours in men was the trunk (40%), on women the upper (32%) and lower limbs (31%).

Conclusions: Melanoma remains a significant health problem, warranting continued prevention efforts. Awareness of differences in presentation by men and women and in different age groups would facilitate improved screening and risk identification.

Statistical analysis

Annual estimates of the Victorian mid-year population by age were obtained from the Australian Bureau of Statistics.11 Age-standardised incidence and incidence by 5-year age band were calculated separately for men and women. Age-standardised incidence was estimated by weighting each 5-year age band incidence by the proportion of the 2015 Victorian population included in this age group. The entire Victorian population was included in the denominator for incidence calculations; we did not adjust for the increasing proportion of the population from ethnic groups at lower risk of melanoma.12

Changes in melanoma incidence were assessed in a joinpoint analysis.13 Joinpoint regression models are useful for assessing changes in incidence trends by identifying combinations of trends that provide a statistically significantly better fit to a data series than a single trend line. The logarithm of the age-standardised rates was assumed to have a linear trend between joinpoints, with errors following a Poisson distribution. Estimated annual percentage

Methods

Data source

We undertook a population-based, descriptive study of registry data. All Victorian Cancer Registry (VCR) records of melanoma diagnosed during 1985–2015 were reviewed. The VCR is managed by Cancer Council Victoria (CCV) on behalf of the Victorian Department of Health and Human Services. Hospitals and pathology laboratories in Victoria are legally required to report details of all diagnosed melanomas. The only inclusion criterion for our study was that patients were Victorian residents at the time of diagnosis. Our primary focus was invasive melanoma. Only the first instance of melanoma for a patient was included in the incidence analysis, consistent with standard international practice.10 Information recorded for each tumour included anatomic site

1 Northern Clinical School, University of Sydney, Sydney, NSW. 2 Royal North Shore Hospital, Sydney, NSW. 3 Peter MacCallum Cancer Centre, Melbourne, VIC.

10.5694/mja17.00725
changes between joinpoints were determined from the fitted trends. Joinpoints were investigated by grid search and additional joinpoints were incrementally tested, with a minimum of four observations between joinpoints.

Cumulative lifetime risk was calculated as the sum of the age group-specific incidence rates, each multiplied by the duration of the age group.

The statistical independence of sex differences in the distribution of anatomic sites (ICD-O-3) and tumour thickness were analysed in \( \chi^2 \) tests, with Bonferroni correction for multiple comparisons. \( P < 0.05 \) was deemed statistically significant.

Calculated and statistical tests were performed with the MATLAB Statistics and Machine Learning Toolbox R2016b (MathWorks) and in Joinpoint 4.3.1.0 (United States National Cancer Institute).

**Ethics approval**

The investigators were granted approval from the CCV for access to and analysis of the data. The protocol for this study was approved by the Northern Sydney Local Health District Human Research Ethics Committee (reference, LNR/17/HAWKE/206).

**Results**

A total of 58 497 invasive melanoma tumours in 53 982 individuals were identified in the VCR; the registry also included 42 351 in situ melanoma tumours diagnosed during 1985–2015. In 2015, the incidence of invasive melanoma was 52.9 cases per 100 000 men and 39.2 cases per 100 000 women. Incidence increased with age for both sexes; in people under 50, the incidence was higher for women than men, but from age 50, the incidence was higher for men (online Appendix, table 1). These differences were reflected in the cumulative lifetime risks of melanoma for men and women in 2015 (Box 1). The cumulative lifetime risks of invasive melanoma at age 75 were 3.7% for men and 2.6% for women; at age 85, however, the cumulative risks were 6.3% and 3.9% respectively.

Joinpoint analysis of trends in age-standardised incidence identified a statistically significant slowing of the increase in incidence of invasive melanoma since the mid-1990s: from 1996 for men \( (P < 0.001) \) and from 1997 for women \( (P = 0.002) \). From 1985 to the joinpoint, the age-standardised incidence increased at an estimated annual rate of 5.3% (95% CI, 3.6–7.1%; \( P < 0.001 \)) for men and at an estimated annual rate of 4.5% (95% CI, 2.9–6.1%; \( P < 0.001 \)) for women. Since the 1996 joinpoint, the age-standardised incidence for men has increased at an estimated annual rate of 0.9% (95% CI, 0.3–1.5%; \( P = 0.006 \)), but for women there has been no significant change since 1997 (estimated annual percentage change, −0.1%; 95% CI, −0.8% to 0.5%, \( P = 0.67 \)) (Box 2).

When trends were analysed by 5-year age group, it was found that the incidence of invasive melanoma increased for both sexes during 1985–2015 for those aged 55 or more; in age groups under 55 years of age, the incidence declined or there was no significant change (data not shown). The age-standardised incidence for all people under 55 years of age increased by 2.7% per year (95% CI, 1.2–4.2%; \( P = 0.001 \)) until 1996, after which it declined by 1.7% per year (95% CI, −2.5% to −0.9%; \( P < 0.001 \)); for those aged 55 or more, the incidence rose by 5.8% per year (95% CI, 4.0–7.6%; \( P < 0.001 \)) until 1996, and after this joinpoint by 1.6% per year (95% CI, 1.0–2.2%; \( P < 0.001 \)). Similar trends applied to both sexes (Box 3).

The anatomic distribution of melanomas differed significantly between men and women \( (P < 0.001) \). The largest proportions of tumours in men were on the trunk (40%), in women on the upper (32%) and lower limbs (31%). Men had a greater proportion of tumours on the face (15% \( v \) 11%) and scalp and neck (10% \( v \) 4%) than women; the proportions of tumours on upper limb and shoulder (32% \( v \) 20%) and lower limb and hip (31% \( v \) 11%) were greater for women than for men (Box 4). The proportion of tumours on the face increased with age (in 2015: < 40 years, 8.3%; \( \geq 80 \) years, 19%; \( > 2 \) mm) was larger in older age groups of both sexes (online Appendix, table 3); the proportion was larger for men than for women (19% \( v \) 14%) (Box 4). Almost two-thirds (66%) of tumours more than 4 mm thick and less than one-third (32%) of those less than 1 mm thick were in people age 70 or more. The scalp and neck were the anatomic sites with the greatest proportion of thick tumours; the site with the greatest proportion of thin tumours were the trunk (32% \( v \) 11%) and scalp and neck (10% \( v \) 4%) (Box 3). The distribution of tumour thickness classes was similar for both sexes in 2015 \( (P = 0.29; \) Box 4), and was fairly constant throughout the study period (data not shown). The proportion of thicker tumours (> 2 mm) was larger in older age groups of both sexes (online Appendix, table 3); the proportion was larger for men than for women (19% \( v \) 14%) (Box 4). Almost two-thirds (66%) of tumours more than 4 mm thick and less than one-third (32%) of those less than 1 mm thick were in people age 70 or more. The scalp and neck were the anatomic sites with the greatest proportion of thick tumours; the site with the greatest proportion of thin tumours was the trunk (online Appendix, table 2).

Finally, 1950 men (6.7%) and 1199 women (4.8%) with a diagnosis of malignant melanoma in our sample were subsequently diagnosed with a further malignant melanoma.

**Discussion**

The incidence and cumulative lifetime risk of invasive melanoma in Victoria was higher in men than in women; in 2015, one in 16 men developed invasive melanoma by the age of 85, compared with one in 26 women. The difference is largely attributable to the higher incidence in older men. Since the mid-1990s, the increase in the incidence of invasive melanoma has slowed in both sexes; in women, the rate has plateaued. The incidence remains higher in more northerly states, but the trends are similar to those in other Australian states and for Australia overall.3,4,8,9 However, our
findings are not congruent with a recent report than the incidence of melanoma is declining in Australia.9 The inconsistency may reflect differences in trends for different states; for example, there is greater latitude in Queensland for improvement because of the relatively higher incidence.2,14 Further, our study covered 4 more years than the earlier report; together with differences in the base populations used for age standardisation, this may also have contributed to our divergent findings.

The incidence of melanoma is higher in Australia and New Zealand than elsewhere in the world,8,9 but is rising in the United States and several European countries, including Norway and Sweden, where the overall incidence is about 30 cases per 100 000 population.8 In Europe, the incidence in several countries has been rising by about 5% each year (eg, Norway and Sweden, 2004–2011; United Kingdom, 1991–2011). However, the incidence of melanoma in New Zealand and the United States appears to have stabilised,8,9 similar to our findings for Victoria.

A promising finding was the declining incidence in people under 55 years of age of both sexes, with annual decreases since the mid-1990s of 1.4% for men and 1.9% for women. Similar age-related differences have been reported in the US.15 More substantial decreases in younger age groups have been reported in Queensland: annual declines of 3.8% (men) and 3.4% (women) for people under 40, and of 2.6% (men) and 1.7% (women) for people aged 40–59 years, with the incidence stable for those aged 60 years or more.14 In Victoria, the overall incidence of melanoma is elevated by the continued increases in incidence among older people, but it may stabilise as the rate of increase in older age groups decreases as currently younger people reach these age groups.

These results attest to the effectiveness of skin cancer prevention campaigns since the early 1980s, such as the Slip! Slop! Slap! and SunSmart campaigns.7 Given the long latency between excessive sun exposure and the clinical presentation of melanoma, the first observable changes attributable to primary prevention campaigns would have reasonably been expected in the mid-1990s.

Skin cancer prevention campaigns also promote early detection, and the slowing increase in the incidence of invasive melanoma may also indicate that more melanomas are being diagnosed while still in situ. Studies in Victoria, other Australian states and overseas have also found that the incidence of melanoma in situ is increasing

<table>
<thead>
<tr>
<th>Age-standardised incidence (2015), per 100 000 population</th>
<th>1985 to joinpoint</th>
<th>P</th>
<th>Joinpoint to 2015</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>52.9</td>
<td>5.3% (3.6–7.1%)</td>
<td>&lt; 0.001</td>
<td>0.9% (0.3–1.5%)</td>
</tr>
<tr>
<td>0–54 years</td>
<td>15.3</td>
<td>2.8% (1.2–4.4%)</td>
<td>0.002</td>
<td>−1.4% (−2.3 to −0.6%)</td>
</tr>
<tr>
<td>≥ 55 years</td>
<td>169.0</td>
<td>6.8% (4.7–8.9%)</td>
<td>&lt; 0.001</td>
<td>1.8% (1.1–2.5%)</td>
</tr>
<tr>
<td>Women</td>
<td>39.2</td>
<td>3.4% (2.0–4.9%)</td>
<td>&lt; 0.001</td>
<td>−0.1% (−0.8 to 0.5%)</td>
</tr>
<tr>
<td>0–54 years</td>
<td>18.8</td>
<td>2.6% (0.8–4.3%)</td>
<td>0.006</td>
<td>−1.9% (−2.8 to −0.9%)</td>
</tr>
<tr>
<td>≥ 55 years</td>
<td>94.5</td>
<td>4.4% (2.9–5.9%)</td>
<td>&lt; 0.001</td>
<td>1.0% (0.4–1.7%)</td>
</tr>
<tr>
<td>Total</td>
<td>46.0</td>
<td>4.5% (2.9–6.1%)</td>
<td>&lt; 0.001</td>
<td>0.5% (−0.1 to 1.1%)</td>
</tr>
<tr>
<td>0–54 years</td>
<td>17.1</td>
<td>2.7% (1.2–4.2%)</td>
<td>0.001</td>
<td>−1.7% (−2.5 to −0.9%)</td>
</tr>
<tr>
<td>≥ 55 years</td>
<td>129.7</td>
<td>5.8% (4.0–7.6%)</td>
<td>&lt; 0.001</td>
<td>1.6% (1.0–2.2%)</td>
</tr>
</tbody>
</table>

Melanoma thickness is a key prognostic marker, and we found that growth in the incidence of invasive melanoma in Australians for the excess risk following a diagnosis of cancer are generally lower than for other countries because of the high background incidence of melanoma. The VCR has previously reported SIRs for men of 7.9 (under 65 years) and 6.6 (65 or over) and for women of 7.3 (under 65 years) and 7.2 (65 or over). We could not calculate accurate SIRs because the population at risk could not be defined without data on deaths.

There is an opportunity to both improve patient health and to achieve economic savings. The cost-effectiveness of skin cancer prevention campaigns has been demonstrated. Similarly, identifying and monitoring patients at high risk of melanoma has been shown to provide better patient outcomes and to be cost-effective. To complement the skin cancer prevention messages that are largely directed to the young, public awareness campaigns could specifically target older people and men to improve earlier detection by encouraging self-screening and having suspicious lesions and moles investigated. Promoting early detection in these groups, in which the incidence of invasive melanoma is highest, could reduce the prevalence of thick tumours, which are associated with poor prognoses and high economic costs.

One limitation of our study was that our analysis was restricted to Victoria. Further, investigating trends in melanoma subtype would also be a useful extension of our analysis.

Our finding that growth in the incidence of invasive melanoma in Victorians under 55 has slowed since the mid-1990s is encouraging. However, complacency is not appropriate. Melanoma remains a significant health problem in Victoria, and its incidence is still increasing in older people. Less encouraging is that the proportion of thicker tumours remains steady and therefore, despite recent progress in systemic therapies, continues to be a problem. The higher rates of thicker tumours in older people show the importance of early detection in these patients, and this should be the focus of public awareness campaigns.

### Competing interests
No relevant disclosures.

Received 28 July 2017, accepted 19 Jan 2018.

© 2018 AMPCo Pty Ltd. Produced with Elsevier B.V. All rights reserved.

---

**4 Anatomical location and thickness of invasive melanoma tumours, Victoria, 2015**

<table>
<thead>
<tr>
<th>Anatomical Site</th>
<th>Total Number of Tumours</th>
<th>Men</th>
<th>Women</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face*</td>
<td>237 (15.3%)</td>
<td>126 (10.7%)</td>
<td>126 (10.7%)</td>
<td>252 (16.7%)</td>
</tr>
<tr>
<td>Scalp/neck</td>
<td>150 (9.7%)</td>
<td>49 (4.2%)</td>
<td>49 (4.2%)</td>
<td>98 (6.4%)</td>
</tr>
<tr>
<td>Trunk</td>
<td>616 (39.6%)</td>
<td>213 (18.1%)</td>
<td>213 (18.1%)</td>
<td>429 (27.7%)</td>
</tr>
<tr>
<td>Upper limb/shoulder</td>
<td>311 (20.0%)</td>
<td>379 (32.2%)</td>
<td>379 (32.2%)</td>
<td>690 (43.3%)</td>
</tr>
<tr>
<td>Lower limb/hip</td>
<td>175 (11.3%)</td>
<td>368 (31.2%)</td>
<td>368 (31.2%)</td>
<td>543 (34.5%)</td>
</tr>
<tr>
<td>Unspecified or overlap</td>
<td>65 (4.2%)</td>
<td>43 (3.7%)</td>
<td>43 (3.7%)</td>
<td>108 (6.9%)</td>
</tr>
</tbody>
</table>

### Breslow thickness

<table>
<thead>
<tr>
<th>Thickness</th>
<th>Total</th>
<th>Men</th>
<th>Women</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 1 mm</td>
<td>921 (59.3%)</td>
<td>769 (65.3%)</td>
<td>769 (65.3%)</td>
<td>1690 (68.1%)</td>
</tr>
<tr>
<td>&gt; 1 mm to 2 mm</td>
<td>214 (13.8%)</td>
<td>158 (13.4%)</td>
<td>158 (13.4%)</td>
<td>372 (15.9%)</td>
</tr>
<tr>
<td>&gt; 2 mm to 4 mm</td>
<td>182 (11.7%)</td>
<td>96 (8.1%)</td>
<td>96 (8.1%)</td>
<td>278 (10.2%)</td>
</tr>
<tr>
<td>&gt; 4 mm</td>
<td>111 (7.1%)</td>
<td>69 (5.9%)</td>
<td>69 (5.9%)</td>
<td>180 (6.6%)</td>
</tr>
</tbody>
</table>

* Includes lip, eyelid, and ear.


